Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.
Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer.
Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in patients with advanced or metastatic lung cancer in combination with docetaxel and endometrial cancer in combination with ipilimumab through a clinical collaboration with Bristol Myers Squibb.
Inspirna identifies novel cancer targets using its microRNA-based target discovery platform, RNA-DRIVEr, which was originally developed by Inspirna’s scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers.
Company Details
- Employees
- 16
- Founded
- -
- Address
- 310 E 67th Street,
- Industry
- Biotechnology
- Website
- http://www.inspirna.com/
- Keywords
- Cancer, Drug Discovery, RNA Biology, Ompenaclid (RGX-202), Abequolixron (RGX-104), RNA-DRIVEr.
- HQ
- New York, NY
Inspirna, Inc. Questions
Inspirna, Inc.'s website is http://www.inspirna.com/
Inspirna, Inc.'s LinkedIn profile is https://www.linkedin.com/company/inspirna
Inspirna, Inc. has
16 employees.
View email and phone details for 16
employees at Inspirna, Inc..
Inspirna, Inc.'s industry is
Biotechnology
Inspirna, Inc.'s top competitors are
Lyndra Therapeutics,
Nkarta, Inc.,
Bioatla, Inc.,
Vaxart, Inc.,
Empyrean Neuroscience,
Lifemine Therapeutics,
Arbutus Biopharma Corporation,
Carisma Therapeutics,
Cytomx Therapeutics,
Cargo Therapeutics.
Inspirna, Inc.'s categories are Biotechnology
Inspirna, Inc.'s founding year is 2010
